{"id":961269,"date":"2026-05-12T07:20:24","date_gmt":"2026-05-12T11:20:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/"},"modified":"2026-05-12T07:20:24","modified_gmt":"2026-05-12T11:20:24","slug":"foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/","title":{"rendered":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WATERTOWN, Mass., May  12, 2026  (GLOBE NEWSWIRE) &#8212; Foghorn<sup>\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n<p>\n        <strong>H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Management will participate in one-on-one meetings on May 19, 2026\n<\/li>\n<\/ul>\n<p>\n        <strong>2026 Stifel Virtual Targeted Oncology Forum\u00a0<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Presentation: Wednesday, May 20, 2026, at 11:00 a.m. EDT<\/li>\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<li>Management will also participate in one-on-one meetings\n<\/li>\n<\/ul>\n<p>\n        <strong>TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA (Virtual)<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">Presentation: Tuesday, May 26, 2026, at 8:30 a.m. EDT<\/li>\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Foghorn Therapeutics<\/strong><br \/>\n        <br \/>Foghorn<sup>\u00ae<\/sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>\u00ae<\/sup> platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kcvdOGmawlKXyaMVbuoept54u7aUIWoyNvxNbjzzr7rEwQhbaFq02siRpmlsLexODy-ezRp4lJ-b918tonO6uKCqeXbG1nAdk7XgPfESP6XC3PN-x2I2gXNOQjG6-IWOtx9W1vFeaVG1byDKXWvUt2tHK6jB36SCMu3a2H3PqbzdSzM4ZWsNJmYWFh9h6xNlD77Winzhi1K6gMxgPvkPc7H2BFvLa-6vRQDmzNnfsKSHu_LUeFI_F3l0Vngfy5No561drRiY4sruNsAtrD2UMw==\" rel=\"nofollow\" target=\"_blank\">www.foghorntx.com<\/a>\u00a0for more information on the Company, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q_J6_kbZjwp4RxYlfJCyqUBI9n8ZNks0YY-f6mqcvJOhO33Me0mWVL8NkEWoKdiwRjqUkOYKroYzyLH9VhAQ380tlLmKXHYqIyCriDaHnZQ57bulZBSCq1rS0lKj7im4lXokETaNNea_KIW6yL2oVYq0GoP5cY6DAUti4m2VeFF2Thjg2Bwc6YOs4CMgiXlvEU4pTSOiTClrCXeDeoQd8g==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lYUzmF9iwFYUshphuOhmwIM8pSJF2ef3iYPuznUp02bJq6auPKR320O1mai5otsh3pC9uq7fb21rfx6ZQM65X9LtY2fEVK8fweDogpZzi2tSeM92ixglMHHsXoFw_-vvm5rioqk0x5j9kXZ4HoX3XWSK-jK_4J4i6epcy4eMZ7pSrJSjNZMSKmyjE7xtC_tZoKf-Ff7qBUKKJC49IGG1w7fa9eZa2THsci7RU7Ga4yKalhsmIecTYDfTN8o31KG8xgTOTQZpfB8US_Cv6my6fw==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Karin Hellsvik, Foghorn Therapeutics Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_xTrecrD58zTyOdbzB0qHV9emH97mcLLKRD4SI_0pNFM352ZE-3af_Gyt8sLUEGYe_aebHFMkjVfOTMdk2NsBipau5jOzebly036RyVu7LM=\" rel=\"nofollow\" target=\"_blank\">khellsvik@foghorntx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmEwODY5NzItYzU0Ny00OGU3LTk0NDUtNmI3N2UwNjk3MWI4LTEyMTQ0MTUtMjAyNi0wNS0xMi1lbg==\/tiny\/Foghorn-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq Management will participate in one-on-one meetings on May 19, 2026 2026 Stifel Virtual &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961269","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq Management will participate in one-on-one meetings on May 19, 2026 2026 Stifel Virtual &hellip; Continue reading &quot;Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T11:20:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May\",\"datePublished\":\"2026-05-12T11:20:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/\",\"name\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\",\"datePublished\":\"2026-05-12T11:20:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk","og_description":"WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq Management will participate in one-on-one meetings on May 19, 2026 2026 Stifel Virtual &hellip; Continue reading \"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T11:20:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May","datePublished":"2026-05-12T11:20:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/"},"wordCount":266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/","name":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=","datePublished":"2026-05-12T11:20:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzczNiM3NTk2NTg4IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961269"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}